Cue Biopharma (CUE)
Develops immune-modulating biologics for autoimmune and allergic diseases.
Something off on this page? Send us feedback.
Develops injectable biologics that selectively modulate disease-specific T cells in vivo. Active programs pair the Immuno-STAT-derived CUE-401 autoimmune candidate with CUE-221, a Phase 2 anti-IgE antibody for allergic diseases licensed outside Greater China.
Develops injectable biologics intended to selectively modulate disease-specific T cells in vivo. Its Immuno-STAT platform underpins CUE-401, which combines engineered IL-2 and TGF-beta signals and is advancing toward Phase 1 for autoimmune and inflammatory disease.
The active pipeline also includes CUE-221, a Phase 2 anti-IgE antibody for allergic diseases, licensed for global rights outside mainland China, Hong Kong, Macau, and Taiwan. Earlier molecules have been licensed to Boehringer Ingelheim and ImmunoScape.
Commercialization depends on further research, clinical testing, potential regulatory approval, and execution under the CUE-221 license and partner arrangements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | B. Riley | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.4M · Total debt $8.8M · Total assets $30.7M · Shareholders' equity $2.3M
- Revenue
- $7.9M
- Operating income
- −$87.7M
- Net income
- −$153.1M
No dividends on record.
| Institutions | 22.60% | 1.64M shares | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Insiders | 9.43% | 685.0K shares | |
| 10 holders · as of Aug 28, 2026 | |||
| Other | 67.97% | 4.94M shares | |
| remainder | |||
7.26M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (7.26M in the company's Sep 23, 2026 report, 2.63M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Shao-Lee Lin1Insiderdirector, officer: Chief Executive Officer | 6.43% | 467,166 | filed Aug 21, 2026 |
Bleichroeder LPInstitution | 5.10% | 370,682 | as of Jun 30, 2026 |
Driehaus Capital Management LLCInstitution | 4.02% | 292,144 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.23% | 161,700 | as of Jun 30, 2026 |
Ikarian Capital, LLCInstitution | 1.44% | 104,364 | as of Jun 30, 2026 |
- Shao-Lee Lin's own ownership statement (13D, Aug 21, 2026) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | Michael Vincent Meluzio | officer: VP, Prin. Accounting Officer | −5,628 | $30.09 |
| Aug 13, 2026 | Sumita Ray | officer, other: Chief Legal Compliance Officer | −8,829 | $30.09 |
| Aug 13, 2026 | Shao-Lee Lin | director, officer: Chief Executive Officer | −18,258 | $28.62 |
| Aug 12, 2026 | Shao-Lee Lin | director, officer: Chief Executive Officer | −40,000 | $27.10 |
| Jun 1, 2026 | Shao-Lee Lin | director, officer: Chief Executive Officer | +136,359 | $3.67 |
- Novartis (ADR)
Marketed anti-IgE benchmark in chronic spontaneous urticaria
- Celldex Therapeutics
Late-stage mast-cell biologic developer in chronic spontaneous urticaria
- Regeneron
Approved IL-4/IL-13 biologic franchise in chronic spontaneous urticaria
- Nektar Therapeutics
Clinical regulatory-T-cell stimulator for immune-mediated disease
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cue Biopharma | $32.55 | +5.34% | $81.2M | — | — | 2.2 | +166.7% |
| Novartis (ADR) | $142.63 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Celldex Therapeutics | $30.85 | −7.95% | $2.23B | — | — | 19,908.1 | −97.0% |
| Regeneron | $798.02 | −0.73% | $82.82B | 19.9 | 13.2 | 5.3 | +16.7% |
| Nektar Therapeutics | $58.87 | −3.44% | $1.75B | — | — | 32.0 | −9.3% |
| Median | 20.6 | 14.2 | 18.7 | −4.2% |